---

Medical Marijuana, Patient Safety, and the Question Modern Medicine Avoids

By James Byrd, MBA

Medical marijuana continues to sit at the intersection of patient demand, regulatory caution, and institutional control. While debate often centers on legality or psychoactivity, a more fundamental issue deserves attention: how cannabis is delivered to patients—and whether current practices truly prioritize patient safety.

Whole-Plant Medicine vs. Pharmaceutical Standards

Cannabis is a complex botanical medicine containing cannabinoids, terpenes, and flavonoids that interact with the human endocannabinoid system. Research increasingly supports the idea that these compounds may work synergistically, often referred to as the “entourage effect” (Russo, 2011).

By contrast, pharmaceutical medicine prioritizes isolated compounds, standardized dosing, and predictability. While this model excels in many areas, it is less suited to therapies derived from biologically complex plants. When treatments fail to conform to this structure, their potential is often narrowed rather than fully explored.

Heating Cannabis: An Overlooked Clinical Risk

One of the most normalized—but least examined—medical cannabis practices is inhalation through smoking or heating.

Clinical literature consistently shows that combusting cannabis produces respiratory irritants, carbon monoxide, and fine particulate matter similar to those found in tobacco smoke (Tashkin, 2013). Even vaporization, while reducing some combustion byproducts, still exposes lung tissue to heated aerosols and ultrafine particles (Abrams et al., 2007).

For patients with:

• compromised immune systems

• chronic lung disease

• cancer or viral susceptibility

these risks are not trivial. Delivery method is not a secondary concern—it is a clinical variable.

Why Topical Application Deserves Serious Consideration

Topical cannabinoids remain underutilized in mainstream medical discussions despite growing evidence supporting their localized, low-risk profile.

Research indicates that cannabinoids applied topically:

• Do not produce psychoactive effects

• Act on peripheral CB2 receptors associated with inflammation and pain

• Avoid pulmonary and gastrointestinal risks

A review in Molecules (2018) notes that topical cannabinoids may be beneficial for inflammatory skin conditions, localized pain, arthritis, and neuropathy without systemic exposure (Palmieri et al., 2019).

From a harm-reduction perspective, topical use aligns closely with foundational medical ethics.

CBD: Promise, Preparation, and the Evidence Gap

CBD has demonstrated therapeutic potential in peer-reviewed research, including anticonvulsant, anti-inflammatory, anxiolytic, and neuroprotective effects (Devinsky et al., 2014; Iffland & Grotenhermen, 2017).

However, studies have repeatedly found that many commercial CBD products:

• Are inaccurately labeled

• Contain inconsistent dosing

• May include contaminants

(JAMA, Bonn-Miller et al., 2017)

When CBD is pharmaceutically standardized, access often becomes limited by cost, insurance coverage, and narrow indications—leaving patients caught between unreliable consumer products and restrictive medical pathways.

Patient Care or System Control?

Modern medicine excels at acute intervention and large-scale standardization. It struggles with therapies that require individualized dosing, nuanced delivery methods, or integrative frameworks.

This tension is not necessarily malicious—but it does create outcomes where risk is amplified and patient autonomy is reduced. When delivery methods compromise safety while narrowing therapeutic benefit, patients have every right to question prevailing norms.

A Call for Better Questions

This is not an argument against medicine. It is an argument for better medicine.

Healthcare progress requires:

• Research free from ideological or commercial bias

• Delivery methods grounded in harm reduction

• Honest acknowledgment of uncertainty

• Respect for informed patient choice

Until safer, better-prepared cannabinoid therapies are widely available, topical application represents a reasonable and responsible interim approach—one that prioritizes patient safety over convenience or control.

Medicine evolves when it listens. Especially to the people it serves.

---

Selected Clinical & Peer-Reviewed References

• Abrams, D. I., et al. (2007). Vaporization as a smokeless cannabis delivery system: A pilot study. Clinical Pharmacology & Therapeutics

• Bonn-Miller, M. O., et al. (2017). Labeling accuracy of cannabidiol extracts sold online. JAMA

• Devinsky, O., et al. (2014). Cannabidiol: Pharmacology and potential therapeutic role in epilepsy. Epilepsia

• Iffland, K., & Grotenhermen, F. (2017). An update on safety and side effects of cannabidiol. Cannabis and Cannabinoid Research

• Palmieri, B., et al. (2019). Cannabinoids in dermatology. Molecules

• Russo, E. B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology

• Tashkin, D. P. (2013). Effects of marijuana smoking on the lung. Annals of the American Thoracic Society

---